Leadership Team

Jerome Charton is a seasoned senior executive with a wealth of experience in global organisations. Prior to joining Clinigen Group as CEO in June 2023, Jerome worked for Arxada, a leading specialty chemicals business, where he was President of the company’s Microbial Control Solutions (MCS) business unit. Prior to his time at Arxada, Jerome enjoyed a successful 12-year tenure at Ecolab, where he held various senior positions before assuming the role of EVP & President of Global Markets, responsible for the company’s operations outside of North America. Earlier in his career, Jerome spent 15 years in commercial and management roles in the healthcare industry, including at Baxter International Inc. and Abbott.

Mike joined Clinigen as Chief Financial Officer in late January 2023, having previously worked for 7 years Bio Products Laboratory (BPL), a leading plasma derived therapeutic medicines company, where he last served in the capacity of President & CFO and Company Director.  During his tenure, Mike helped to more than double BPL’s therapeutic business revenue, while making significant investments in capacity, reliability, IT and productivity projects across the company’s global footprint, setting it up for its next stage of growth.  Prior to BPL, Mike developed his career and experience at the US multinational General Electric over 19 years, holding various senior finance roles both in the US as well as in Europe, across the Energy, Industrial Solutions, and Software divisions. Mike holds a dual bachelor’s degree in Finance and Economics from Boston College’s Carroll School of Management. 

Prior to joining Clinigen in 2010 David worked in sales, marketing and finance roles for GSK and Wyeth Pharmaceuticals where he was responsible for the development and commercialisation of phase II, III and marketed oncology products across Europe, the Middle East and North Africa. David joined Clinigen to set up the Unlicensed Medicines Business and was part of the executive team that took Clinigen through its IPO in 2012, and subsequently ran the Global Specialty Pharmaceutical Division. For the last seven years David has headed up the Corporate Development division.